This is a research study to find out if Qutenza 8% capsaicin topical system is safe and effective when treating subjects with lower back pain (LBP) that is caused by damage at or near the nerve's root in the lower back leg (lumbosacral radiculopathy) which is pain that can move all the way down the back of the leg. The pain may also start outside of the spinal cord, in the peripheral nerves and may also be felt all the way down the back of the leg (neuropathic LBP). Qutenza 8% capsaicin, the study drug, is currently FDA approved to treat nerve pain after a shingles outbreak in addition to a type of nerve pain in the feet associated with diabetes. In this study a maximum of four patches per visit (sized 14cm x 20 cm) will be used to deliver the Qutenza 8% capsaicin to the participants skin.
If a subject meets the qualifications for this study, in addition to their standard of care for their LBP, they can expect to have a total of 5 visits in a 12 month period. Each visit will require subjects to fill out several surveys and receive treatment patches for their LBP (your doctor will decide if participants will need to be retreated at each visit based on your symptoms). The study visits are estimated to take 90 minutes upwards to 120 minutes.

Start Date13 Mar 2025

Sponsor / Collaborator

Medical University of South Carolina

[+1]

NCT06444919

/ RecruitingPhase 4IIT

Capsaicin in Digital Osteoarthritis Versus Control : a Randomized Study

The objective of this multicentric, randomized controlled double-blind clinical trial is to demonstrate the efficacy of transdermal application of capsaicin in patients with painful digital osteoarthritis with a neuropathic pain component.
Participants will receive either a transdermal patch of capsaicin 179 mg (8%) or the control treatment (capsaicin 0.04%).
Researchers will compare the intensity of pain in the fingers at day 60 in the capsaicin 8% group versus capsaicin 0.04% (control arm)

Start Date07 Mar 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Clermont Ferrand

[+1]

100 Clinical Results associated with Capsaicin

100 Translational Medicine associated with Capsaicin

100 Patents (Medical) associated with Capsaicin

18,043

Literatures (Medical) associated with Capsaicin

01 Sep 2025·TALANTA

Deep eutectic solvent-induced coacervation in micellar solution of alkyl polyglucoside surfactant: Supramolecular solvent formation and application in food analysis

Article

Author: Tobiszewski, Marek ; Yahya, Lutfi Andre ; Vakh, Christina ; Makoś-Chełstowska, Patrycja

The number of deep eutectic solvents were investigated to induce coacervation and cause phase separation in the micellar solution of the alkyl polyglucoside C₈-C₁₀. Three fatty acids were selected as hydrogen bond donors namely hexanoic acid, heptanoic acid, and octanoic acid, while quaternary ammonium salts and a monoterpenoid thymol were used as hydrogen bond acceptors to obtain deep eutectic solvents. The precursors of the deep eutectic solvents could be incorporated into the micelle structure of alkyl polyglucoside C₈-C₁₀ and modulate its properties, improving the interaction with the target compounds and promoting phase separation due to the increasing size of the micellar aggregates. The synergy of green surfactant and deep eutectic solvent has been demonstrated in the determination of capsaicinoids as secondary metabolites retaining the pungency of chili peppers and, thus, of spicy foods. Extraction recoveries were above 75 % for target analytes. The limits of detection were found to be 1.7 μg g ^-1 for capsaicin and dihydrocapsaicin. The relative recoveries were in the range of 76 -130 %. The research presented is the first example of synergy between alkyl polyglucoside and deep eutectic solvent. The proposed extraction system has the potential to be used in many other analytical tasks, especially in the analysis of solid and heterogeneous samples. Not only fatty acid-based deep eutectic solvents but other based on alcohols, monoterpenoids, etc. can also be used for coacervation. Thus, wide range of already studied deep eutectic solvents could be investigated for this purpose.

01 Jun 2025·AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL

Renal nerve afferents drive preferential renal sympathoexcitation in response to acute renal ischemia/reperfusion in rats

Article

Author: Gil, C D ; Campos, R R ; Knuepfer, M M ; Carvalhal, R S ; Bergamaschi, C T ; Marreiros, A C ; Nishi, E E ; Lantyer, R ; Santos, D D ; Milanez, M I O

Renal nerve activity is composed of afferent (sensory) and efferent (sympathetic) nerve activity. Ischemia/reperfusion (IR) of the kidney increases renal sympathetic nerve activity (rSNA) and depresses renal function. As the role of renal afferent fibers in acute renal IR is unclear, we tested the hypothesis that renal IR increases rSNA triggered by renal afferent nerves responding to acute ischemia. Two experimental series were performed in adult male Wistar rats. IR was induced by total obstruction of blood flow to the left kidney by clamping the renal artery for 60 min and reperfusion for 120 min. We recorded MAP, HR, rSNA, and splanchnic sympathetic vasomotor activity (sSNA) in 8 normal IR rats and 6 left kidney deafferented IR rats (IR ARD). Renal deafferentation was performed using capsaicin administration to the left renal nerve 2 weeks before the experiments. Blood samples were collected before ischemia and at the end of reperfusion for total and differential leukocyte counts. Renal ischemia significantly increased rSNA 23 % (20 min: 0,07 ± 0,04mVs P < 0.05) but not sSNA. The increase in rSNA was triggered by activation of renal afferent fibers, since IR significantly reduced rSNA in the IR ARD group maximal decrease in frequency 22 % (180 min: -62 ± 29Δspikes/s) and in amplitude 41 % (-0,29 ± 0, 12mVs, P < 0.05) and induced hypotension and bradycardia. However, no significant difference was observed between groups in blood leukocyte profile, but a significant reduction in renal IL-6 was found in IR ARD, suggesting a reduction in renal inflammation in deafferented IR rats. The results show that renal afferent nerves trigger a preferential increase in rSNA and inflammation in the kidney during acute IR.

01 May 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Investigation of the participation of the TRPV1 receptor in the irritant effect of dithranol in mice

Article

Author: Ferreira, Juliano ; Prudente, Arthur Silveira ; Lückemeyer, Debora Denardin ; da Silva, Ana Merian ; Schran, Roberta Giusti ; de Amorim Ferreira, Marcella

Dithranol is one of the most effective topical medications for treating plaque psoriasis. However, its clinical use is limited by irritative adverse reactions to the skin, such as oedema, erythema, and pruritus, caused by poorly understood mechanisms. Because TRPV1 activation mediates skin irritation caused by several drugs, we conducted blind and randomised experiments in male and female C57BL/6 mice to elucidate the role of TRPV1 in dithranol-induced irritation. Dithranol (0.01%-0.5%) or vehicle was applied topically to the right ear of the animals. Oedema, erythema, and pruritus were monitored from 2 h to 6 days after application. Treatment with 0.5% dithranol caused oedema and erythema, but not pruritus, starting at 6 h, reaching its highest point at 1 day, and persisting up to 6 days after treatment, mainly in male mice. The 0.1% dose induced erythema but not oedema. Interestingly, topical application of 1% capsaicin was shown to defunctionalise TRPV1-positive fibres and did not influence early irritation caused by dithranol (2 h-2 days). However, it increased the late phase of irritation (5-6 days). Similarly, salicylate did not reduce the early irritation caused by dithranol but also increased the late phase. Antagonism by SB366791 and 4-tert-butylcyclohexanol did not alter skin irritation. Our results suggest that, contrary to our initial hypothesis, TRPV1 appears to act protectively against skin irritation caused by dithranol, particularly in the late stage.

News (Medical) associated with Capsaicin

21 Mar 2025

·www.drugs.com

Not Much Works To Soothe Low Back Pain, Study Says

FRIDAY, March 21, 2025 -- There are a ton of suggestions out there for soothing an aching lower back -- acupuncture, heat, cannabinoids, muscle relaxants, TENS electrical pulses, dry cupping, opioids, massage and more. But not much actually eases back pain, including those suggestions, according to a new evidence review. Only painkillers like aspirin or ibuprofen -- non-steroidal anti-inflammatory drugs (NSAIDs) -- have been shown to be moderately effective in treating short-term lower back pain based on available medical evidence, researchers concluded. There’s also some evidence that five other treatments might help long-term low back pain, researchers said -- exercise , spinal manipulation, taping, antidepressants and warming creams containing ingredients like capsaicin . Overall, only 10% of treatments for low back pain had any medical evidence supporting their potential effectiveness, and even they didn’t work that great, concluded the review in the journal BMJ Evidence-Based Medicine . “Surprisingly, we found only around one in 10 was effective and most provided pain relief that was only marginally better than placebo – in other words, our review did not find reliable evidence of large effects for any of the included treatments,” Aidan Cashin , deputy director of the Center for Pain IMPACT at Neuroscience Research Australia, said in a news release. Non-surgical treatments are considered first-line care for back pain, Cashin said. Researchers performed the evidence review to see just how well these myriad therapies work. For the review, they analyzed findings from 301 clinical trials examining 56 treatments or treatment combinations for low back pain. Results showed that no sure-fire cures for back pain are currently available. Even ones with some evidence behind them can’t be counted on to work well for everyone. “We found for acute low back pain, NSAIDs may be effective. For chronic low back pain, exercise, spinal manipulation, taping, antidepressants and TRPV1 agonists (warming creams) may be effective,” Cashin said. “However, those effects were small.” Researchers also specifically highlighted five treatments that don’t work, based on the evidence. These included three for short-term low back pain – exercise, steroid injections and acetaminophen – and two for chronic back pain, antibiotics and anesthetics. For the rest of the treatments included in the research, there was simply not enough evidence to rule one way or the other, researchers concluded. More research is needed to prove whether or not these other back pain cures might have something to them. “We need further high-quality, placebo-controlled trials to understand the efficacy of treatments and remove the uncertainty for both patients and clinical teams,” Cashin said. “Placebo-controlled studies are the gold standard for evaluating the effects of treatments, with a clear need to better understand which treatments work for people with low back pain,” he added. In the meantime, Cashin recommends that people with back pain talk to their medical team to understand the treatments available and find one that works best for them. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

24 Feb 2025

·www.prnewswire.com

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

TORONTO and AACHEN, Germany, Feb. 24, 2025 /PRNewswire/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management and related diseases, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain. Under the agreement, Searchlight Pharma ("Searchlight"), Apotex's specialty pharma division, will pursue marketing authorization for Qutenza and market and distribute Qutenza in Canada upon regulatory approval. Grünenthal will receive an upfront payment in addition to regulatory milestone payments and royalties. This agreement further reinforces Apotex's dedication to meeting the needs of patients with innovative solutions and expands Apotex's global portfolio of more than 550 branded, generic, and biosimilar pharmaceutical products. "Licensing the Canadian rights to Qutenza enables us to improve the lives of Canadians by increasing the options for advanced pain management, specifically by bringing to Canada a differentiated and novel agent for the treatment of neuropathic pain that is already commercialized in the EU and US markets," said Mark Nawacki, President of Searchlight. "This agreement demonstrates our continued momentum along our Journey of Health growth strategy and our dedication to enhancing patient care." "We have continuously developed Qutenza to expand its footprint and reach more patients in need – most notably through a relaunch and label extension in the US," says Jan Adams, Chief Commercial Officer at Grünenthal. "Apotex's exceptional commercial capabilities make them the ideal partner for us to tap into the Canadian market, one of the largest pharmaceutical markets in the world. We look forward to serving Canadian patients with this non-systemic, non-opioid treatment option and moving closer to our vision of a world free of pain." Grünenthal acquired the global rights to Qutenza® in 2018 as part of its growth strategy. Since 2017, the company has invested more than €2 billion in successful M&A transactions and continues to generate additional value by integrating the acquired brands into Grünenthal's infrastructure, creating synergies throughout manufacturing, logistics, and commercial activities. About Qutenza ® In Europe, Qutenza is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit . Qutenza (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at . About Apotex and Searchlight Pharma Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Searchlight Pharma, the specialty pharma division of Apotex, executes best-in-class search, acquisition, and focused development of innovative and unique specialty healthcare products, with a core of its promoted products focused on women's health, dermatology, allergy, pain management and hospital specialty markets. Learn more about us at and at . About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the US Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion. More information: Follow us on: LinkedIn: Grunenthal Group | Instagram: grunenthal Media contacts: Apotex: [email protected] Grünenthal Florian Dieckmann, Head Global Corporate Affairs +49 241 569-2555 [email protected] SOURCE Apotex Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalLicense out/inAcquisition

07 Nov 2024

·www.prnewswire.com

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures1, thus affecting more than 3 million people with surgical procedures per year in the U.S.2 QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025, and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data. AACHEN, Germany and MORRISTOWN, N.J., Nov. 7, 2024 /PRNewswire/ -- Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and tolerability of QUTENZA® (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) and if successful could support an extension of the U.S. label. "Patients who undergo surgery and end up developing post-surgical neuropathic pain, may experience debilitating complications that often are not treated appropriately," says Lizandra Marcondes, M.D., PhD, Senior VP Medical Affairs & Drug Safety US, Averitas Pharma. "We believe QUTENZA® may be a clinically meaningful treatment option that could address the unmet needs of many patients in the United States who suffer from Post-surgical neuropathic pain and may not be satisfied with available oral, systemically acting medicines. We look forward to completing the Clinical Trial with the goal to file a supplemental new drug application to the U.S. Food and Drug Administration (FDA) in 2026, assuming positive data." AV001 is a randomized, double-blind 42-week trial including 410 patients who have been suffering from moderate to severe PSNP for at least six months. The primary endpoint of the trial is a reduction in the average pain intensity after 12 weeks compared to baseline. In addition, the trial assesses other outcomes including reduction in the average pain intensity after 42-weeks, progressive response over time with repeated treatment, reduction of the treatment area over several applications, and quality of life outcomes such as sleep interference, physical activity, anxiety, and depression. When completed, AV001 will be the first blinded randomized controlled trial in post-surgical neuropathic pain that evaluates the long-term treatment effects of a topical neuropathic pain treatment. "The completion of enrollment is an exciting milestone. With our current indications, adults with painful diabetic peripheral neuropathy of the feet and postherpetic neuralgia, we have advanced the trajectory of QUTENZA® in the U.S. by expanding access to a much-needed non-opioid therapy option for a large, underserved patient population," adds Marv Kelly, President Averitas Pharma. "By adding post-surgical neuropathic pain to the U.S. label if results are positive, we would have the potential to fill an unmet treatment need for additional patients in pain." When Grünenthal acquired the US-rights for Qutenza® in 2018, the US-label comprised the treatment of neuropathic pain associated with postherpetic neuralgia. Since then, Grünenthal re-launched the product and significantly increased patients' access to Qutenza®. In 2020, the U.S. FDA approved the product for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. With AV001, Grünenthal and Averitas hope to include another major indication in the field of peripheral neuropathic pain in the U.S. label. Topline results are anticipated in Q4 2025 and, assuming positive data, Averitas Pharma aims to submit a supplemental new drug application (sNDA) in 2026. About QUTENZA QUTENZA (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia, and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important U.S. safety information is available below and at . In Europe, QUTENZA is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain. For further information please visit . About post-surgical neuropathic pain Post-surgical neuropathic pain (PSNP) is defined as chronic pain that develops after a surgical procedure and persists beyond the healing process, i.e., at least three months after the surgery. The pain is either localized to the surgical field or area of injury, projected to the innervation territory of a nerve situated in this area, or referred to a dermatome (after surgery/injury to deep somatic or visceral tissues).3 It is identified by symptoms of neuropathic nerve pain such as burning, stabbing or shooting pain, numbness, and changes to physical sensation or sensitivity to temperature or touch. PSNP occurs after approximately 10 percent of all surgical procedures1, thus affecting more than 3 million people with surgical procedures per year in the U.S.2 About Averitas Pharma, Inc. Averitas Pharma is a specialty pharmaceutical company dedicated to delivering innovative, effective, non-opioid pain management options to patients in the U.S. The company was formed in 2018 as a subsidiary of GRT U.S. Holding, Inc. and member of the Grünenthal Group. For more information, visit . Follow us on LinkedIn: About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion. More information: Follow us on: LinkedIn: Grunenthal Group Instagram: grunenthal For further information, please contact: Christopher Jansen, Global Corporate Affairs Phone: +49 241 569-1428 [email protected] Florian Dieckmann, Head Global Corporate Affairs Phone: +49 241 569-2555 [email protected] IMPORTANT US-SAFETY INFORMATION Do not dispense QUTENZA to patients for self-administration or handling. Use only on dry, unbroken skin. Only physicians or healthcare professionals are to administer and handle QUTENZA, following the procedures in the label. Warnings and Precautions Severe Irritation: Whether applied directly or transferred accidentally from other surfaces, capsaicin can cause severe irritation of eyes, mucous membranes, respiratory tract, and skin to the healthcare professional, patients, and others. Do not use near eyes or mucous membranes, including face and scalp. Take protective measures, including wearing nitrile gloves and not touching items or surfaces that the patient may also touch. Flush irritated mucous membranes or eyes with water and provide supportive medical care for shortness of breath. Remove affected individuals from the vicinity of QUTENZA. Do not re-expose affected individuals to QUTENZA if respiratory irritation worsens or does not resolve. If skin not intended to be treated comes into contact with QUTENZA, apply Cleansing Gel and then wipe off with dry gauze. Thoroughly clean all areas and items exposed to QUTENZA and dispose of properly. Because aerosolization of capsaicin can occur with rapid removal, administer QUTENZA in a well-ventilated area, and remove gently and slowly, rolling the adhesive side inward. Application-Associated Pain: Patients may experience substantial procedural pain and burning upon application and following removal of QUTENZA. Prepare to treat acute pain during and following application with local cooling and/or appropriate analgesic medication. Increase in Blood Pressure: Transient increases in blood pressure may occur with QUTENZA treatment. Monitor blood pressure during and following treatment procedure and provide support for treatment-related pain. Patients with unstable or poorly controlled hypertension, or a recent history of cardiovascular or cerebrovascular events, may be at an increased risk of adverse cardiovascular effects. Consider these factors prior to initiating QUTENZA treatment. Sensory Function: Reductions in sensory function (generally minor and temporary) have been reported following administration of QUTENZA. Assess for signs of sensory deterioration or loss prior to each application of QUTENZA. If sensory loss occurs, treatment should be reconsidered. Severe Application Site Burns: Full-thickness (third-degree) and deep partial-thickness (second-degree) burns have been reported following administration of QUTENZA. Cases of full-thickness (third-degree) burns, requiring hospitalization and skin grafting have been reported in patients who received QUTENZA for an unapproved indication and/or frequency of dosing at an application site where there had been prior skin trauma. Ensure that dosage and administration recommendations are followed. Adverse Reactions The most common adverse reactions (≥5% and > control group) in all controlled clinical trials are application site erythema, application site pain, and application site pruritus. To report SUSPECTED ADVERSE REACTIONS, contact Averitas Pharma, Inc. at 1-877-900-6479 or FDA at 1-800-FDA-1088 or . Please see full Prescribing Information. 1 Rosenberger DC, Pogatzki-Zahn EM. Chronic post-surgical pain - update on incidence, risk factors and preventive treatment options. BJA Educ. 2022 May;22(5):190-196. doi: 10.1016/j.bjae.2021.11.008. Epub 2022 Feb 24. 2 (Accessed November 2024) 3 ICD 11 - SOURCE Grünenthal Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug Approval

100 Deals associated with Capsaicin

External Link

KEGG	Wiki	ATC	Drug Bank
D00250	Capsaicin	M02AB01 N01BX04	DB06774

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic peripheral neuropathic pain	United States	Averitas Pharma, Inc.Startup	17 Jul 2020
Neuralgia, Postherpetic	United States	Averitas Pharma, Inc.Startup	16 Nov 2009
Neuralgia	China	Changchun Pan-Chinapharm Co. Ltd.	24 Jan 2003
Pain	China	Changchun Pan-Chinapharm Co. Ltd.	24 Jan 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peripheral Nervous System Diseases	Phase 3	France	Grünenthal GmbH	20 Oct 2023
Pain, Postoperative	Phase 3	United States	Averitas Pharma, Inc.Startup	13 Jul 2021
Pain, Postoperative	Phase 3	France	Averitas Pharma, Inc.Startup	13 Jul 2021
Pain, Postoperative	Phase 3	Netherlands	Averitas Pharma, Inc.Startup	13 Jul 2021
Pain, Postoperative	Phase 3	Poland	Averitas Pharma, Inc.Startup	13 Jul 2021
Pain, Postoperative	Phase 3	Spain	Averitas Pharma, Inc.Startup	13 Jul 2021
Pain, Postoperative	Phase 3	United Kingdom	Averitas Pharma, Inc.Startup	13 Jul 2021
Breast Cancer	Phase 3	France	Grünenthal GmbH	19 Mar 2019
Diabetic peripheral neuropathy	Phase 3	Belgium	Astellas Pharma, Inc.	01 Nov 2011
Diabetic peripheral neuropathy	Phase 3	Czechia	Astellas Pharma, Inc.	01 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2024	Not Applicable	Dyspepsia \| Gastroesophageal Reflux \| Severe asthma	-	CAPSAICIN (GERD (+))	spcgqpjnsa(rmkkjyilcv) = vxqkxcdkkf ksawpmvlfo (fkkmclfctt )	-	13 Oct 2024
NCT03722849 (CTgov)	Not Applicable	Refractory chronic cough	58	Functional Brain Imaging+Capsaicin+Adenosine Triphosphate (Chronic Cough Participant)	ilqwtpvbtl(owgyyznoyp) = qoykkwtjlj uavetwjpfu (qzosbvjgkp, 0.60) View more	-	22 Aug 2024
				Functional Brain Imaging+Capsaicin+Adenosine Triphosphate (Healthy Control Participant)	ilqwtpvbtl(owgyyznoyp) = vzhtlqtjmj uavetwjpfu (qzosbvjgkp, 0.47) View more
ADA2024	Not Applicable	Diabetic Neuropathies	-	High Concentration Capsaicin Topical System (HCCTS)	dyvoeufyls(clwfzrizgl) = snmqvsvryi chbhdknzps (lzjpsuwpds ) View more	-	14 Jun 2024
NCT04918069 (Pubmed)	Phase 3	Chemotherapy-induced nausea and vomiting	160	Topical Capsaicin 0.075%	elgzynkrdv(itypqzsqko) = qxknylszho vejmhmhatk (qopylbfeuh ) View more	Positive	01 Jun 2024
				Placebo	hhfbljrkgv(gxgylthhft) = npuubfcnzl zlntphfvwg (pttpiyglmt ) View more
NCT05298202 (CTgov)	Phase 4	Heat Exhaustion	12	Hot environment+Capsaicin (Capsaicin Gel Application)	slkxprazei(fqfughyrus) = fiapilotrb ttfeqqkddg (lihvnudbsf, 104.9) View more	-	15 Mar 2024
				Control Gel (Hypoallergenic Gel Application)	slkxprazei(fqfughyrus) = zhxlnyzkyh ttfeqqkddg (lihvnudbsf, 56.7) View more
NCT04256733 (CTgov)	Early Phase 1	Cough	19	Supra-threshold (Supra-threshold Capsaicin)	npftisopdo(gpzqdptmro) = wsrhlaerhg vdtligvgmp (eqcvjyadvy, 1.78) View more	-	04 Mar 2024
				Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer (Sub-threshold Capsaicin)	npftisopdo(gpzqdptmro) = xfxnifltzz vdtligvgmp (eqcvjyadvy, 2.48) View more
EBCC2022	Not Applicable	Adjuvant	35	Capsaicin patch 179 mg	tkkkdnymgw(rjuihlszvz) = fjobfjzzft rhkofvofae (ccykusajax ) View more	-	17 Nov 2022
UEGW2022	Not Applicable	Deglutition Disorders TRPV1 agonist	51	Capsaicin 10Õ¼m	bjfihtjuep(wfryystyuu) = ollrtyxfym zbgexvddgg (mwhjzwgiip ) View more	Positive	09 Oct 2022
				Placebo	bjfihtjuep(wfryystyuu) = gjgvxwzelk zbgexvddgg (mwhjzwgiip )
NCT03429049 (CTgov)	Phase 3	Osteoarthritis, Knee	332	Placebo (Placebo)	ubdaxabelu(ymhfdhixhw) = gssptfucwq nzaqmorpby (ehnebmpexm, 0.212) View more	-	08 Apr 2022
				CNTX-4975-05 (CNTX-4975-05)	ubdaxabelu(ymhfdhixhw) = wuhxuyahzy nzaqmorpby (ehnebmpexm, 0.182) View more
UEGW2021	Not Applicable	Pain	-	Capsaicin perfusion	gjjmwrhtaa(lwgyoelpbn) = impaired recovery of the baseline impedance compared to saline-treated controls cdyolrpgra (vcjoujzjiz )	-	02 Oct 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis